In a phase 3 RCT of 507 adults with Parkinson disease and motor fluctuations on levodopa, tavapadon vs placebo increased daily good-on-time by 1.10 hours at week 26 (P<.001); adverse events were more frequent (71.7% vs 55.1%), mostly mild to moderate.
RCTn = 507
Fernandez et al. Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical Trial